Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group.
- 1 October 1993
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis and Thrombosis: A Journal of Vascular Biology
- Vol. 13 (10), 1412-1417
- https://doi.org/10.1161/01.atv.13.10.1412
Abstract
A case-control comparison within the framework of the prospective, multidisciplinary PLAT Study was performed to assess whether altered baseline fibrinolytic variables were associated with an elevated risk of ischemic thrombotic events in patients with documented coronary, cerebral, and/or peripheral atherosclerotic disease. Fibrinogen, D-dimer, tissue plasminogen activator (t-PA) antigen, and fibrinolytic activity before and after venous stasis (delta = difference between the two values), t-PA inhibitor, and lipid levels in 60 atherosclerotic patients with a thrombotic event during the first year of follow-up were compared with those in 94 atherosclerotic patients without such events, who were matched for age, sex, and diagnosis at enrollment. Events were associated with a higher release of delta t-PA antigen (P = .047), higher D-dimer (P = .024), and higher t-PA inhibitor (P = .001) levels. delta Fibrinolytic activity was correlated inversely with t-PA inhibitor (P < .01) and triglycerides (P < .05). D-Dimer was also correlated with systolic blood pressure (P < .01). Atherosclerotic patients at higher risk of thrombotic ischemic events are characterized by increased fibrin turnover and impaired fibrinolytic activity due to high t-PA inhibitor levels. This hemostatic disequilibrium may participate with conventional risk factors such as elevated triglyceride levels and systolic blood pressure in the multifactorial mechanism of ischemic sequelae in patients with preexisting vascular atherothrombotic disease.Keywords
This publication has 20 references indexed in Scilit:
- Endogenous tissue-type plasminogen activator and risk of myocardial infarctionThe Lancet, 1993
- Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic anginaAmerican Heart Journal, 1992
- Antithrombin III and arterial diseaseThe Lancet, 1991
- The PLAT Study: a multidisciplinary study of hemostatic function and conventional risk factors in vascular disease patientsAtherosclerosis, 1991
- Plasma D‐dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable statesBritish Journal of Haematology, 1989
- Fibrin and Fibrinogen-Related Antigens in Patients with Stable and Unstable Coronary Artery DiseaseNew England Journal of Medicine, 1987
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985
- [Rank Transformations as a Bridge Between Parametric and Nonparametric Statistics]: CommentThe American Statistician, 1981
- Gerinnungsphysiologische Schnellmethode zur Bestimmung des FibrinogensActa Haematologica, 1957